Phase 1 Insights From KYN-5356, a Novel KAT-II Inhibitor, for Cognitive Impairment Associated with Schizophrenia
- How KYN 5356, a first in class KAT II inhibitor, targets the kynurenine pathway to address CIAS, a major unmet driver of disability in schizophrenia
- Phase 1 results demonstrating excellent safety, tolerability, and robust CNS penetration with favorable plasma and CSF pharmacokinetics
- Evidence of target engagement through dose dependent reductions in CSF kynurenic acid and EEG improvements linked to cognitive pathways
- Early signals of cognitive improvement supporting progression to Phase 2 trials in CIAS and broader precision medicine applications